Document text
BioNTech SE 01/29/2021
An der Goldgrube 12
Mainz N/A
Germany 55131215-280-5503
COVID-19 Vaccine (BNT162, PF-07302048) 019736
Prophylactic immunization against COVID-19 in adults
16 years of age
Phase 4
BB-IND 013812, BB-IND 013278, BLA 125549
0 1 9 5
3
FDA-CBER-2021 5683-1072480
Özlem Türeci, MD, Chief Medical Officer, BioNTech SE
Özlem Türeci, MD, Chief Medical Officer, BioNTech SE
Neda Aghajani Memar, Pharm.D., Senior Manager, Pfizer Global Regulatory Affairs - Vaccines
212-733-2613 (845) 474-3500
235 East 42nd Street
219/9/69
New York NY
United States of America [email protected]
01/29/2021
United States of America
Neda Aghajani
MemarDigitally signed by Neda Aghajani Memar
DN: cn Neda Aghajani Memar, o, ou,
email [email protected], c US
Reason: I attest to the accuracy and integrity of this
document
Date: 2021.01.29 12:50:16 -05'00'
3
FDA-CBER-2021-5683-1072481
3
FDA-CBER-2021-5683-1072482